Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Multiple Sclerosis

Free Subscription Articles published in J Neurol Retrieve available abstracts of 258 articles: HTML format

Single Articles

October 2025
1. AHMAD R, Jackson-Tarlton CS, Flanagan EP, Messina S, et al
   Critical demyelinating lesions in progressive multiple sclerosis: a prospective observational study.
   J Neurol. 2025;272:677.
   PubMed     Abstract available
   
   
   September 2025
2. WAGSHUL ME, Nayak S, Foley FW, Motl RW, et al
   Grey matter atrophy patterns of mobility shared across older adults with and without multiple sclerosis.
   J Neurol. 2025;272:656.
   PubMed     Abstract available
   
   
   
3. ROMANO F, Rocca MA, Pagani E, Amato MP, et al
   Effects of cognitive rehabilitation and exercise on brain structure in progressive multiple sclerosis: results from the CogEx trial.
   J Neurol. 2025;272:645.
   PubMed     Abstract available
   
   
   
4. MORENO-NAVARRO L, Mora-Diaz S, Ruiz-Escribano-Menchen L, Sempere AP, et al
   Kappa free light chain index as a diagnostic and prognostic biomarker in multiple sclerosis.
   J Neurol. 2025;272:646.
   PubMed     Abstract available
   
   
   
5. HABEK M, Adamec I, Gabelic T, Barun B, et al
   Diagnostic performance of the 2010, 2017, and 2024 McDonald criteria: clinical implications in multiple sclerosis.
   J Neurol. 2025;272:637.
   PubMed     Abstract available
   
   
   
6. ALONI R, Dror C, Barazani T, Kalron A, et al
   Wartime stress and relapse risk in people with multiple sclerosis: a prospective cohort study.
   J Neurol. 2025;272:619.
   PubMed     Abstract available
   
   
   
7. YANG J, Li H, Zhang Y, Hu S, et al
   Effects of exercise on fatigue and quality of life in multiple sclerosis: a network meta-analysis and systematic review.
   J Neurol. 2025;272:621.
   PubMed     Abstract available
   
   
   
8. ELLENBERGER D, Frahm N, Stahmann A, Warnke C, et al
   Age-related differences in switching highly effective disease-modifying therapy in patients with multiple sclerosis.
   J Neurol. 2025;272:609.
   PubMed     Abstract available
   
   
   
9. ASLAN D, Bourabia S, Kowall B, Straukiene A, et al
   The impact of autoimmune comorbidities on multiple sclerosis progression: insights from a longitudinal single-center study.
   J Neurol. 2025;272:607.
   PubMed     Abstract available
   
   
   August 2025
10. KEVER A, Kang N, Meza C, Pogacar M, et al
    Not for everyone: examining predictors of cognitive rehabilitation success in multiple sclerosis.
    J Neurol. 2025;272:593.
    PubMed    
    
    
    
11. MATHEY G, Epstein J, Alix T, Julien M, et al
    Cerebrospinal fluid levels of chitinase 3-like 1 and interleukin-6 can predict response to platform therapies in relapsing multiple sclerosis.
    J Neurol. 2025;272:592.
    PubMed     Abstract available
    
    
    
12. ADAMMEK F, Gralla W, Kupjetz M, Rademacher A, et al
    Functional exercise training in persons with multiple sclerosis: a systematic review.
    J Neurol. 2025;272:590.
    PubMed     Abstract available
    
    
    
13. REEVES JA, Tranquille A, Bartnik A, Mohebbi M, et al
    Paramagnetic rim lesions are associated with choroid plexus inflammation and expansion over 5 years in people with multiple sclerosis.
    J Neurol. 2025;272:585.
    PubMed     Abstract available
    
    
    
14. SCANDIFFIO J, Langer LK, Senthilnathan V, Feng G, et al
    Effects of psychological therapies in people with multiple sclerosis: a systematic review and network meta-analysis of randomized controlled trials.
    J Neurol. 2025;272:584.
    PubMed     Abstract available
    
    
    
15. GUERRIERI S, Gattuso I, Genchi A, Nozzolillo A, et al
    Stratify and ImmunoWELL JCV tests performances in a real-world multiple sclerosis cohort: possible clinical implications of biosimilar Natalizumab use.
    J Neurol. 2025;272:583.
    PubMed    
    
    
    
16. ABBADESSA G, Maida E, Bonavita S, Lavorgna L, et al
    First the B cells fall, then the T cells follow: temporal immunological shift with ocrelizumab in multiple sclerosis.
    J Neurol. 2025;272:582.
    PubMed     Abstract available
    
    
    
17. JAWORSKI M 3RD, Balconi J, Santivasci C, Youngs M, et al
    Improving conscientiousness through a smartphone app and telecoaching intervention: insights from multiple sclerosis and healthy aging samples.
    J Neurol. 2025;272:580.
    PubMed     Abstract available
    
    
    
18. SBAIHAT H, Roenneke K, Muller D, Ladopoulos T, et al
    MRI-based human brain atlases of R1, R2, proton density, and myelin volume fraction using synthetic quantitative imaging at 1.5 T.
    J Neurol. 2025;272:578.
    PubMed     Abstract available
    
    
    
19. ALFREDSSON L, Guo J, Johansson E, Olsson T, et al
    Early-life and adult body mass index in relation to MS disability progression.
    J Neurol. 2025;272:571.
    PubMed     Abstract available
    
    
    
20. FILIPPI M, Amato MP, Centonze D, Gallo P, et al
    The use of high-efficacy disease-modifying therapies in multiple sclerosis: recommendations from an expert Delphi consensus.
    J Neurol. 2025;272:565.
    PubMed     Abstract available
    
    
    
21. LEITNER U, Chew SH, Blanch J, Viswanathan M, et al
    Characteristics of MRI lesions in AQP4 antibody-positive NMOSD, MOGAD, and multiple sclerosis: a systematic review and meta-analysis.
    J Neurol. 2025;272:560.
    PubMed     Abstract available
    
    
    
22. MANISCALCO GT, Sparaco M, Di Gregorio M, Cafasso G, et al
    Real-world comparison of lymphopenia profiles in S1P receptor modulators for multiple sclerosis: a multicenter retrospective study.
    J Neurol. 2025;272:559.
    PubMed     Abstract available
    
    
    
23. KERITAM O, Ascoli O, Harsanyi A, Cetin H, et al
    Advanced multiple sclerosis: an exploratory study on a neglected patient population.
    J Neurol. 2025;272:553.
    PubMed     Abstract available
    
    
    
24. MENASCU S, Drori T, Kalron A
    Subcortical brain volume changes linked to concern of falling in multiple sclerosis: a structural MRI study.
    J Neurol. 2025;272:552.
    PubMed     Abstract available
    
    
    July 2025
25. DE SOUZA WAGNER PH, de Paiva FA, Mello JS, Silva ALM, et al
    Clinical outcomes after switching from fingolimod to B-cell-depleting therapies in multiple sclerosis: systematic review and meta-analysis.
    J Neurol. 2025;272:546.
    PubMed     Abstract available
    
    
    
26. DINI M, Tacchini M, Gamberini G, Boschetti A, et al
    Learning as a digital hallmark of cognition in multiple sclerosis: lessons from a digital symbol digit modalities test.
    J Neurol. 2025;272:536.
    PubMed     Abstract available
    
    
    
27. FUNG WH, Wessels MHJ, Coerver EME, de Beukelaar J, et al
    Reliability of serum neurofilament light and glial fibrillary acidic protein for detecting disease activity upon discontinuation of first-line disease-modifying therapy in stable multiple sclerosis (DOT-MS).
    J Neurol. 2025;272:530.
    PubMed     Abstract available
    
    
    
28. VITTURI BK, Cellerino M, Boccia D, Leray E, et al
    Environmental risk factors for multiple sclerosis: a comprehensive systematic review and meta-analysis.
    J Neurol. 2025;272:513.
    PubMed     Abstract available
    
    
    
29. COLEMAN A, Touze A, Farag M, Pengo M, et al
    Evaluating finger-prick blood collection for remote quantification of neurofilament light in neurological diseases.
    J Neurol. 2025;272:501.
    PubMed     Abstract available
    
    
    
30. NICOLELLA V, Varelli M, Fasano S, Sirica R, et al
    Clinical application of age-derived cut-offs for plasma neurofilament light chain in multiple sclerosis.
    J Neurol. 2025;272:495.
    PubMed     Abstract available
    
    
    
31. CAGOL A, Schaedelin S, Ocampo-Pineda M, Benkert P, et al
    Comparative effectiveness of teriflunomide and ocrelizumab on smoldering activity in multiple sclerosis: an observational study in the Swiss Multiple Sclerosis Cohort.
    J Neurol. 2025;272:491.
    PubMed     Abstract available
    
    
    June 2025
32. ZACCONE T, Moiola L, Guerrieri S, Nozzolillo A, et al
    Long-term effectiveness and safety of ocrelizumab: a single-centre real-world study.
    J Neurol. 2025;272:481.
    PubMed     Abstract available
    
    
    
33. VERCELLINO M, Marasciulo S, Bosa C, Rolando A, et al
    Added value of spinal cord MRI in detecting active disease in non-relapsing progressive multiple sclerosis patients.
    J Neurol. 2025;272:482.
    PubMed     Abstract available
    
    
    
34. NAUTA IM, Loughlin KNM, Gravesteijn AS, van Wegen J, et al
    A multi-domain lifestyle intervention in multiple sclerosis: a longitudinal observational study.
    J Neurol. 2025;272:476.
    PubMed     Abstract available
    
    
    
35. BURGUET VILLENA F, Cerda-Fuertes N, Hofer L, Schadelin S, et al
    Retinal neuronal loss and progression independent of relapse activity in multiple sclerosis.
    J Neurol. 2025;272:454.
    PubMed     Abstract available
    
    
    
36. ZANETTA C, Gasperini C, Amato MP, Centonze D, et al
    Potential use of the SARS-CoV-2 monoclonal antibody sipavibart in people with multiple sclerosis: definition of different patient archetypes from an Italian expert group perspective.
    J Neurol. 2025;272:446.
    PubMed     Abstract available
    
    
    
37. CHEN H
    A disproportionality analysis of nervous system adverse events associated with disease-modifying therapies in multiple sclerosis: insights from the FDA adverse event reporting system (FAERS).
    J Neurol. 2025;272:445.
    PubMed     Abstract available
    
    
    
38. MALUCCHI S, Bava CI, Valentino P, Martire S, et al
    Correction: In multiple sclerosis patients a single serum neurofilament light chain (sNFL) dosage is strongly associated with 12 months outcome: data from a real-life clinical setting.
    J Neurol. 2025;272:444.
    PubMed    
    
    
    May 2025
39. NEYAL N, Krey KJ, Morrison HA, Nathoo N, et al
    From checkboxes to emojis: a novel approach to patient-reported outcomes in multiple sclerosis.
    J Neurol. 2025;272:434.
    PubMed     Abstract available
    
    
    
40. CLARELLI F, Corona A, Paakkonen K, Sorosina M, et al
    Correction: Pharmacogenomics of clinical response to Natalizumab in multiple sclerosis: a genome-wide multi-centric association study.
    J Neurol. 2025;272:423.
    PubMed    
    
    
    
41. GASPERINI C, Centonze D, Conte A, Gallo P, et al
    Personalized therapy in multiple sclerosis: an Italian Delphi consensus.
    J Neurol. 2025;272:428.
    PubMed     Abstract available
    
    
    
42. GIOFRE F, Lugaresi A, Baccari F, Lui E, et al
    The topography of infratentorial lesions in depression and anxiety in multiple sclerosis.
    J Neurol. 2025;272:420.
    PubMed     Abstract available
    
    
    
43. DAVIES L, Shehadeh R, Watkins WJ, Jolles S, et al
    Real-world observational study of infections in people treated with ocrelizumab for multiple sclerosis.
    J Neurol. 2025;272:415.
    PubMed     Abstract available
    
    
    
44. ZHANG Y, Li G, Su H, Liang Y, et al
    Effects of exercise on balance function in people with multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials.
    J Neurol. 2025;272:405.
    PubMed     Abstract available
    
    
    
45. GERVASONI E, Torchio A, Bertoni R, Chieffo R, et al
    Beyond EDSS: multidomain impairments are detectable and associated with walking disorders in low-disabled people with multiple sclerosis.
    J Neurol. 2025;272:404.
    PubMed     Abstract available
    
    
    
46. FREEDMAN MS, Abdelhak A, Bhutani MK, Freeman J, et al
    The role of serum neurofilament light (sNfL) as a biomarker in multiple sclerosis: insights from a systematic review.
    J Neurol. 2025;272:400.
    PubMed     Abstract available
    
    
    
47. TARANU D, Balz LT, Holbrook J, Tumani V, et al
    Cognitive impairment, mood, and fatigue in various multiple sclerosis subtypes: a one-year follow-up study.
    J Neurol. 2025;272:398.
    PubMed     Abstract available
    
    
    
48. ROCCA MA, Ratzinger S, Preziosa P, Meani A, et al
    Clinical integration of brain and cord MRI features improves differential diagnosis of multiple sclerosis.
    J Neurol. 2025;272:388.
    PubMed     Abstract available
    
    
    
49. FILIPPI M, Preziosa P, Rocca MA
    Randomized controlled trials for multiple sclerosis: integrating pathology-driven outcomes to capture therapeutic efficacy.
    J Neurol. 2025;272:385.
    PubMed    
    
    
    
50. FREEDMAN DE, Oh J, Einstein G, Feinstein A, et al
    Aging and the neuropsychiatry of multiple sclerosis: a cross-sectional study.
    J Neurol. 2025;272:375.
    PubMed     Abstract available
    
    
    
51. KOLB H, Shachaf Y, Fainberg K, Golan M, et al
    Intrathecal methotrexate in progressive multiple sclerosis: a phase 1 open-label study with long-term follow-up.
    J Neurol. 2025;272:374.
    PubMed     Abstract available
    
    
    
52. HERMAN D, Tanniou J, Leray E, Pierret C, et al
    Analyzing recurrent events in multiple sclerosis: a review of statistical models with application to the MSOAC database.
    J Neurol. 2025;272:371.
    PubMed     Abstract available
    
    
    
53. KUUTTI K, Laakso SM, Viitala M, Atula S, et al
    Mortality and causes of death for people with multiple sclerosis: a Finnish nationwide register study.
    J Neurol. 2025;272:370.
    PubMed     Abstract available
    
    
    April 2025
54. CACCIAGUERRA L, Madhavan A, Sechi E, Krecke KN, et al
    Utility of spinal cord axial-T2 sequence in a population-based cohort of multiple sclerosis.
    J Neurol. 2025;272:367.
    PubMed    
    
    
    
55. MAHMOUDI N, Renne J, Konen FF, Jendretzky KF, et al
    Added value of optic nerve lesions for multiple sclerosis diagnostic criteria.
    J Neurol. 2025;272:358.
    PubMed     Abstract available
    
    
    
56. LEAVITT V, Mostert J, Comtois J, Moral E, et al
    Measuring cognitive change in secondary progressive MS: an analysis of the ASCEND cognition substudy.
    J Neurol. 2025;272:338.
    PubMed     Abstract available
    
    
    
57. BALSHI A, Dempsey J, Kumbar S, Leuenberger G, et al
    Correction: Marriage is associated with decreased lesion volumes and less brain atrophy in people with multiple sclerosis.
    J Neurol. 2025;272:337.
    PubMed    
    
    
    
58. OJHA A, Tommasin S, Piervincenzi C, Baione V, et al
    Clinical and MRI features contributing to the clinico-radiological dissociation in a large cohort of people with multiple sclerosis.
    J Neurol. 2025;272:327.
    PubMed     Abstract available
    
    
    
59. HONG J, Gaubert M, Lefort M, Ferre JC, et al
    Limited added value of systematic spinal cord MRI vs brain MRI alone to classify patients with MS as active or inactive during follow-up.
    J Neurol. 2025;272:316.
    PubMed     Abstract available
    
    
    
60. MOIOLA L, Mandelli A, Tarkowski M, Finardi A, et al
    Recall vaccination increases detectable B-cell reactivity in persons with multiple sclerosis treated with ocrelizumab.
    J Neurol. 2025;272:314.
    PubMed     Abstract available
    
    
    
61. LADOPOULOS T, Abbas Z, Krieger B, Bellenberg B, et al
    Neurological disability and brain grey matter atrophy in primary progressive multiple sclerosis are determined by microstructural lesional changes, but not by lesion load.
    J Neurol. 2025;272:302.
    PubMed     Abstract available
    
    
    March 2025
62. KONITSIOTI AM, Laurent S, Ellenberger D, Stahmann A, et al
    MS treatment trends before, during, and after the COVID-19 pandemic: insights from the German MS Register.
    J Neurol. 2025;272:294.
    PubMed     Abstract available
    
    
    
63. LADEIRA F, Nobrega C, Cerqueira J
    Evaluation of the efficacy of the SARS-CoV-2 vaccine additional and booster doses in immunocompromised patients with multiple sclerosis: the COVACiMS study.
    J Neurol. 2025;272:288.
    PubMed     Abstract available
    
    
    
64. BOSTAN M, Li C, Cheong JW, Wong DWK, et al
    Longitudinal analysis of retinal and choriocapillaris in patients with multiple sclerosis: a 3-year study.
    J Neurol. 2025;272:237.
    PubMed     Abstract available
    
    
    February 2025
65. AZZIMONTI M, Preziosa P, Pagani E, Meani A, et al
    Cervical spinal cord gray matter damage predicts disability worsening in multiple sclerosis: a longitudinal study.
    J Neurol. 2025;272:228.
    PubMed     Abstract available
    
    
    
66. SCHONHERR C, Ziegler J, Zentek T, Rashid A, et al
    Smartphone-based gait analysis in the assessment of fatigue and fatigability in people with multiple sclerosis: a supervised cohort study.
    J Neurol. 2025;272:217.
    PubMed     Abstract available
    
    
    
67. BALSHI A, Dempsey J, Manning N, Leuenberger G, et al
    A disproportionality analysis of surgical site infections across multiple sclerosis disease modifying therapies.
    J Neurol. 2025;272:223.
    PubMed     Abstract available
    
    
    
68. NAYAK S, Wagshul ME, Foley FW, Motl RW, et al
    Associations between connectivity in functional brain networks and gait speed in older adults with and without multiple sclerosis.
    J Neurol. 2025;272:216.
    PubMed     Abstract available
    
    
    
69. DI SABATINO E, Ferraro D, Gaetani L, Emiliano E, et al
    CSF biomarkers of B-cell activation in multiple sclerosis: a clinical perspective.
    J Neurol. 2025;272:211.
    PubMed     Abstract available
    
    
    
70. MARASTONI D, Sicchieri M, Pizzini FB, Scartezzini A, et al
    Multiple sclerosis diagnosis and its differential diagnosis in patients presenting with type four 'mirror pattern' CSF oligoclonal bands.
    J Neurol. 2025;272:207.
    PubMed     Abstract available
    
    
    
71. FILIPPI M, Amato MP, Avolio C, Gallo P, et al
    Towards a biological view of multiple sclerosis from early subtle to clinical progression: an expert opinion.
    J Neurol. 2025;272:179.
    PubMed     Abstract available
    
    
    January 2025
72. GIANNOPAPAS V, Smyrni V, Kitsos DK, Stefanou MI, et al
    Cancer in multiple sclerosis patients following prolonged exposure to disease-modifying therapies (DMTs): a systematic review and meta-analysis.
    J Neurol. 2025;272:162.
    PubMed     Abstract available
    
    
    
73. INOJOSA H, Schriefer D, Ness NH, Dillenseger A, et al
    Cost-consequence analysis of early vs. delayed natalizumab use in highly active relapsing-remitting multiple sclerosis: a simulation study.
    J Neurol. 2025;272:153.
    PubMed     Abstract available
    
    
    
74. PIHL-JENSEN G, Frederiksen JL
    The value of magnetic resonance imaging of the optic nerve for the diagnosis of multiple sclerosis in patients with optic neuritis.
    J Neurol. 2025;272:131.
    PubMed     Abstract available
    
    
    
75. LAGEMAN SB, Jolly A, Sahi N, Prados F, et al
    Explaining cognitive function in multiple sclerosis through networks of grey and white matter features: a joint independent component analysis.
    J Neurol. 2025;272:142.
    PubMed     Abstract available
    
    
    
76. MIRMOSAYYEB O, Weinstock-Guttman B, Zivadinov R, Jakimovski D, et al
    Anatomy-driven segmentation of parafoveal optical coherence tomography (OCT) measures may improve associations with clinical outcomes in multiple sclerosis.
    J Neurol. 2025;272:141.
    PubMed     Abstract available
    
    
    
77. BALSHI A, Dempsey J, Kumbar S, Leunberger G, et al
    Marriage is associated with decreased lesion volumes and less brain atrophy in people with multiple sclerosis.
    J Neurol. 2025;272:151.
    PubMed     Abstract available
    
    
    
78. MAR S, Valeriani M, Steinborn B, Schreiner T, et al
    Ocrelizumab dose selection for treatment of pediatric relapsing-remitting multiple sclerosis: results of the OPERETTA I study.
    J Neurol. 2025;272:137.
    PubMed     Abstract available
    
    
    
79. MAIWORM M, Koerbel K, Anschutz V, Jakob J, et al
    BDNF levels in serum and CSF are associated with clinicoradiological characteristics of aggressive disease in MS patients.
    J Neurol. 2025;272:147.
    PubMed     Abstract available
    
    
    
80. PREZIOSA P, Pagani E, Meani A, Margoni M, et al
    Soma and neurite density abnormalities of paramagnetic rim lesions and core-sign lesions in multiple sclerosis.
    J Neurol. 2025;272:145.
    PubMed     Abstract available
    
    
    
81. PLESS S, Woelfle T, Lorscheider J, Wiencierz A, et al
    CoGames: Development of an adaptive smartphone-based and gamified monitoring tool for cognitive function in Multiple Sclerosis.
    J Neurol. 2025;272:119.
    PubMed     Abstract available
    
    
    
82. ZANGHI A, Greco A, Giancipoli E, Tumani H, et al
    Unraveling the inflammation-degeneration tangle in early MS: preliminary insights from ferritin, neurogranin, TREM2, and retinal ganglion cell layer.
    J Neurol. 2025;272:109.
    PubMed     Abstract available
    
    
    
83. ROBERTSON NP
    Bruton's tyrosine kinase inhibitor for multiple sclerosis: new hope or false dawn.
    J Neurol. 2025;272:106.
    PubMed     Abstract available
    
    
    
84. WALBAUM M, Madhukar A, Dobson R, Cyhlarova E, et al
    Cost effectiveness of different treatment strategies with natalizumab for pregnant women with multiple sclerosis.
    J Neurol. 2025;272:93.
    PubMed     Abstract available
    
    
    
85. FILIPPI M, Gallo P, Gasperini C, Marfia GA, et al
    Implementing proximity care for people with multiple sclerosis in Italy: the bottom-up approach of the StayHome project.
    J Neurol. 2025;272:96.
    PubMed     Abstract available
    
    
    December 2024
86. NICOLESCU M, Haussler V, Paul F, Oertel FC, et al
    Visual quality of life in NMOSD and MOGAD: profiles, dynamics and associations with ageing and vision.
    J Neurol. 2024;272:86.
    PubMed     Abstract available
    
    
    
87. BARBA L, Gaetani L, Sperandei S, Di Sabatino E, et al
    CSF synaptic biomarkers and cognitive impairment in multiple sclerosis.
    J Neurol. 2024;272:85.
    PubMed     Abstract available
    
    
    
88. MIRMOSAYYEB O, Yazdan Panah M, Moases Ghaffary E, Vaheb S, et al
    Magnetic resonance imaging-based biomarkers of multiple sclerosis and neuromyelitis optica spectrum disorder: a systematic review and meta-analysis.
    J Neurol. 2024;272:77.
    PubMed     Abstract available
    
    
    
89. FILIPPI M, Margoni M, Zaccone T, Guerrieri S, et al
    Disability worsening outcome in multiple sclerosis based on EDSS: does half a point matter?
    J Neurol. 2024;272:9.
    PubMed    
    
    
    
90. VECCHIO D, Puricelli C, Virgilio E, Passarelli F, et al
    Kappa index for multiple sclerosis diagnosis: an accurate biomarker of intrathecal synthesis.
    J Neurol. 2024;272:30.
    PubMed     Abstract available
    
    
    
91. PONZIO M, Santoni L, Molina M, Tavazzi E, et al
    Economic burden of multiple sclerosis in an Italian cohort of patients on disease-modifying therapy: analysis of disease cost and its components.
    J Neurol. 2024;272:50.
    PubMed     Abstract available
    
    
    
92. DE BLASIIS P, Massimiani A, Inglese C, Bianchini E, et al
    Spasticity patterns assessment and recognition for therapeutic approaches (SPARTA) in multiple sclerosis: a multicenter epidemiological study.
    J Neurol. 2024;272:34.
    PubMed     Abstract available
    
    
    
93. GASPERINI C, Battaglia MA, Balzani F, Chiarini E, et al
    Unveiling preferences in multiple sclerosis care: insights from an Italian discrete-choice experiment with patients and healthcare professionals.
    J Neurol. 2024;272:27.
    PubMed     Abstract available
    
    
    
94. COMABELLA M, Hegen H, Villar LM, Rejdak K, et al
    Increased EBNA1-specific antibody response in primary-progressive multiple sclerosis.
    J Neurol. 2024;272:26.
    PubMed     Abstract available
    
    
    November 2024
95. PAKEERATHAN T, Havla J, Schwake C, Salmen A, et al
    Rapid differentiation of MOGAD and MS after a single optic neuritis.
    J Neurol. 2024;271:7222-7231.
    PubMed     Abstract available
    
    
    October 2024
96. FACCIORUSSO S, Malfitano C, Giordano M, Del Furia MJ, et al
    Effectiveness of robotic rehabilitation for gait and balance in people with multiple sclerosis: a systematic review.
    J Neurol. 2024 Oct 10. doi: 10.1007/s00415-024-12715.
    PubMed     Abstract available
    
    
    
97. SELMAJ K, Hartung HP, Mycko MP, Selmaj I, et al
    MS treatment de-escalation: review and commentary.
    J Neurol. 2024;271:6426-6438.
    PubMed     Abstract available
    
    
    September 2024
98. MALUCCHI S, Bava CI, Valentino P, Martire S, et al
    In multiple sclerosis patients a single serum neurofilament light chain (sNFL) dosage is strongly associated with 12 months outcome: data from a real-life clinical setting.
    J Neurol. 2024 Sep 23. doi: 10.1007/s00415-024-12701.
    PubMed     Abstract available
    
    
    
99. MARGONI M, Valsasina P, Moiola L, Mistri D, et al
    Monoaminergic network abnormalities are associated with fatigue in pediatric multiple sclerosis.
    J Neurol. 2024 Sep 19. doi: 10.1007/s00415-024-12689.
    PubMed     Abstract available
    
    
    
100. YOUSEF H, Malagurski Tortei B, Castiglione F
     Predicting multiple sclerosis disease progression and outcomes with machine learning and MRI-based biomarkers: a review.
     J Neurol. 2024 Sep 12. doi: 10.1007/s00415-024-12651.
     PubMed     Abstract available
     
     
     
101. CLARELLI F, Corona A, Paakkonen K, Sorosina M, et al
     Pharmacogenomics of clinical response to Natalizumab in multiple sclerosis: a genome-wide multi-centric association study.
     J Neurol. 2024 Sep 12. doi: 10.1007/s00415-024-12608.
     PubMed     Abstract available
     
     
     
102. CALLEN AM, Zurawski J, Chu R, Tie Y, et al
     The role of 7 T MRI to assess atrophy of the subcortical deep gray matter in relapsing-remitting multiple sclerosis.
     J Neurol. 2024 Sep 6. doi: 10.1007/s00415-024-12656.
     PubMed     Abstract available
     
     
     
103. DELUCA J
     Correction to: Fatigue in multiple sclerosis: can we measure it and can we treat it?
     J Neurol. 2024 Sep 6. doi: 10.1007/s00415-024-12630.
     PubMed    
     
     
     
104. PORTACCIO E, Betti M, De Meo E, Addazio I, et al
     Correction to: Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progression.
     J Neurol. 2024 Sep 4. doi: 10.1007/s00415-024-12627.
     PubMed    
     
     
     
105. GIOSSI R, Mercenari M, Filippi M, Zanetta C, et al
     Correction to: Unprescribed cannabinoids and multiple sclerosis: a multicenter, cross-sectional, epidemiological study in Lombardy, Italy.
     J Neurol. 2024 Sep 3. doi: 10.1007/s00415-024-12560.
     PubMed    
     
     
     August 2024
106. WURDACK K, Pruss H, Finke C
     Evolution from viral encephalitis to autoimmune encephalitis to multiple sclerosis: a case report.
     J Neurol. 2024 Aug 31. doi: 10.1007/s00415-024-12659.
     PubMed     Abstract available
     
     
     
107. CHISARI CG, Amato MP, Di Sapio A, Foschi M, et al
     Active and non-active secondary progressive multiple sclerosis patients exhibit similar disability progression: results of an Italian MS registry study (ASPERA).
     J Neurol. 2024 Aug 27. doi: 10.1007/s00415-024-12621.
     PubMed     Abstract available
     
     
     
108. CAROTENUTO A, Di Monaco C, Papetti L, Borriello G, et al
     Pediatric-onset Multiple Sclerosis treatment: a multicentre observational study comparing natalizumab with fingolimod.
     J Neurol. 2024 Aug 23. doi: 10.1007/s00415-024-12610.
     PubMed     Abstract available
     
     
     
109. SIMONE M, Lucisano G, Guerra T, Paolicelli D, et al
     Disability trajectories by progression independent of relapse activity status differ in pediatric, adult and late-onset multiple sclerosis.
     J Neurol. 2024 Aug 23. doi: 10.1007/s00415-024-12638.
     PubMed     Abstract available
     
     
     
110. MISCIOSCIA A, Mainero C, Treaba CA, Silvestri E, et al
     The contribution of paramagnetic rim and cortical lesions to physical and cognitive disability at multiple sclerosis clinical onset: evaluating the power of MRI and OCT biomarkers.
     J Neurol. 2024 Aug 19. doi: 10.1007/s00415-024-12622.
     PubMed     Abstract available
     
     
     
111. ARNETT SV, Prain K, Ramanathan S, Bhuta S, et al
     Long-term outcomes of ADEM-like and tumefactive presentations of CNS demyelination: a case-comparison analysis.
     J Neurol. 2024;271:5275-5289.
     PubMed     Abstract available
     
     
     
112. ZIVADINOV R, Jakimovski D, Burnham A, Kuhle J, et al
     Neuroimaging assessment of facility-bound severely-affected MS reveals the critical role of cortical gray matter pathology: results from the CASA-MS case-controlled study.
     J Neurol. 2024;271:4949-4962.
     PubMed     Abstract available
     
     
     July 2024
113. FILIPPI M, Pagani E, Turrini R, Bartezaghi M, et al
     Effects of fingolimod on focal and diffuse damage in patients with relapsing-remitting multiple sclerosis - The "EVOLUTION" study.
     J Neurol. 2024 Jul 29. doi: 10.1007/s00415-024-12590.
     PubMed     Abstract available
     
     
     
114. MANZANO GS, Levy M, Salky R, Mateen FJ, et al
     Assessment of international MOGAD diagnostic criteria in patients with overlapping MOG-associated disease and multiple sclerosis phenotypes.
     J Neurol. 2024 Jul 27. doi: 10.1007/s00415-024-12585.
     PubMed     Abstract available
     
     
     
115. PASSALI M, Galea I, Knudsen MH, Lau LC, et al
     Cerebrospinal fluid neurofilament light chain in acute optic neuritis and its predictive ability of multiple sclerosis.
     J Neurol. 2024 Jul 25. doi: 10.1007/s00415-024-12587.
     PubMed     Abstract available
     
     
     
116. KARL AS, Klimas R, Katsimpoura M, Sgodzai M, et al
     Quality of life and tolerability of B-cell directed therapy of multiple sclerosis with ofatumumab in a patient-centered real-world observational study.
     J Neurol. 2024 Jul 22. doi: 10.1007/s00415-024-12581.
     PubMed     Abstract available
     
     
     
117. MOLENAAR PCG, Noteboom S, van Nederpelt DR, Krijnen EA, et al
     Digital outcome measures are associated with brain atrophy in patients with multiple sclerosis.
     J Neurol. 2024 Jul 15. doi: 10.1007/s00415-024-12516.
     PubMed     Abstract available
     
     
     
118. RAVANO V, Andelova M, Piredda GF, Sommer S, et al
     Microstructural characterization of multiple sclerosis lesion phenotypes using multiparametric longitudinal analysis.
     J Neurol. 2024 Jul 13. doi: 10.1007/s00415-024-12568.
     PubMed     Abstract available
     
     
     
119. VITI V, Zanetta C, Capra R, Municchi A, et al
     Ocrelizumab-associated enteritis in patients with multiple sclerosis: an emerging safety issue.
     J Neurol. 2024 Jul 11. doi: 10.1007/s00415-024-12553.
     PubMed    
     
     
     
120. DELUCA J
     Fatigue in multiple sclerosis: can we measure it and can we treat it?
     J Neurol. 2024 Jul 5. doi: 10.1007/s00415-024-12524.
     PubMed     Abstract available
     
     
     
121. ROT U, Jerala M, Horvat Ledinek A, Brecl Jakob G, et al
     Progressive multifocal leukoencephalopathy in association with siponimod treatment for secondary progressive multiple sclerosis: a case report.
     J Neurol. 2024 Jul 3. doi: 10.1007/s00415-024-12542.
     PubMed    
     
     
     
122. KAPPOS L, Edan G, Freedman MS, Hartung HP, et al
     Long-term clinical outcomes in patients with CIS treated with interferon beta-1b: results from the 15-year follow up of the BENEFIT trial.
     J Neurol. 2024;271:4599-4609.
     PubMed     Abstract available
     
     
     
123. ZANGHI A, Borriello G, Bonavita S, Fantozzi R, et al
     Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score matched study.
     J Neurol. 2024;271:4495-4502.
     PubMed     Abstract available
     
     
     
124. HARTUNG HP, Berger T, Bermel RA, Brochet B, et al
     ENSEMBLE PLUS: final results of shorter ocrelizumab infusion from a randomized controlled trial.
     J Neurol. 2024;271:4348-4360.
     PubMed     Abstract available
     
     
     
125. MAKHANI N, Lebrun-Frenay C, Siva A, Shabanova V, et al
     The diagnostic workup of children with the radiologically isolated syndrome differs by age and by sex.
     J Neurol. 2024;271:4019-4027.
     PubMed     Abstract available
     
     
     June 2024
126. LAL AP, Foong YC, Sanfilippo PG, Spelman T, et al
     A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic.
     J Neurol. 2024 Jun 27. doi: 10.1007/s00415-024-12518.
     PubMed     Abstract available
     
     
     
127. NOTEBOOM S, Seiler M, Chien C, Rane RP, et al
     Evaluation of machine learning-based classification of clinical impairment and prediction of clinical worsening in multiple sclerosis.
     J Neurol. 2024 Jun 23. doi: 10.1007/s00415-024-12507.
     PubMed     Abstract available
     
     
     
128. SIMANI L, Molaeipour L, Kian S, Leavitt VM, et al
     Correlation between cognitive changes and neuroradiological changes over time in multiple sclerosis: a systematic review and meta-analysis.
     J Neurol. 2024 Jun 18. doi: 10.1007/s00415-024-12517.
     PubMed     Abstract available
     
     
     
129. GIOSSI R, Mercenari M, Filippi M, Zanetta C, et al
     Unprescribed cannabinoids and multiple sclerosis: a multicenter, cross-sectional, epidemiological study in Lombardy, Italy.
     J Neurol. 2024 Jun 7. doi: 10.1007/s00415-024-12472.
     PubMed     Abstract available
     
     
     May 2024
130. PORTACCIO E, Betti M, De Meo E, Addazio I, et al
     Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progression.
     J Neurol. 2024 May 28. doi: 10.1007/s00415-024-12448.
     PubMed     Abstract available
     
     
     
131. MONTEIRO I, Nicolella V, Fiorenza M, Novarella F, et al
     The ocrelizumab wearing-off phenomenon is associated with reduced immunomodulatory response and increased neuroaxonal damage in multiple sclerosis.
     J Neurol. 2024 May 23. doi: 10.1007/s00415-024-12434.
     PubMed     Abstract available
     
     
     
132. CORTESE R, Battaglini M, Stromillo ML, Luchetti L, et al
     Regional hippocampal atrophy reflects memory impairment in patients with early relapsing remitting multiple sclerosis.
     J Neurol. 2024 May 14. doi: 10.1007/s00415-024-12290.
     PubMed     Abstract available
     
     
     
133. WOLF E, Wicklein R, Aly L, Schmaderer C, et al
     Optical coherence tomography angiography suggests different retinal pathologies in multiple sclerosis and Sjogren's syndrome.
     J Neurol. 2024 May 14. doi: 10.1007/s00415-024-12414.
     PubMed     Abstract available
     
     
     
134. FREEDMAN DE, Oh J, Kiss A, Puopolo J, et al
     The influence of depression and anxiety on cognition in people with multiple sclerosis: a cross-sectional analysis.
     J Neurol. 2024 May 11. doi: 10.1007/s00415-024-12409.
     PubMed     Abstract available
     
     
     
135. BARDEL B, Creange A, Bonardet N, Bapst B, et al
     Motor function in multiple sclerosis assessed by navigated transcranial magnetic stimulation mapping.
     J Neurol. 2024 May 6. doi: 10.1007/s00415-024-12398.
     PubMed     Abstract available
     
     
     
136. GALPERIN I, Buzaglo D, Gazit E, Shimoni N, et al
     Gait and heart rate: do they measure trait or state physical fatigue in people with multiple sclerosis?
     J Neurol. 2024 May 2. doi: 10.1007/s00415-024-12339.
     PubMed     Abstract available
     
     
     
137. ROCCA MA, Romano F, Tedone N, Filippi M, et al
     Advanced neuroimaging techniques to explore the effects of motor and cognitive rehabilitation in multiple sclerosis.
     J Neurol. 2024 May 1. doi: 10.1007/s00415-024-12395.
     PubMed     Abstract available
     
     
     
138. PREZIOSA P, Rocca MA, Filippi M
     Radiologically isolated syndromes: to treat or not to treat?
     J Neurol. 2024;271:2370-2378.
     PubMed     Abstract available
     
     
     April 2024
139. DIMAURO KA, Swetlik C, Cohen JA
     Management of multiple sclerosis in older adults: review of current evidence and future perspectives.
     J Neurol. 2024 Apr 30. doi: 10.1007/s00415-024-12384.
     PubMed     Abstract available
     
     
     
140. ROSENSTEIN I, Nordin A, Sabir H, Malmestrom C, et al
     Association of serum glial fibrillary acidic protein with progression independent of relapse activity in multiple sclerosis.
     J Neurol. 2024 Apr 26. doi: 10.1007/s00415-024-12389.
     PubMed     Abstract available
     
     
     
141. NAUTA IM, van Dam M, Bertens D, Kessels RPC, et al
     Improved quality of life and psychological symptoms following mindfulness and cognitive rehabilitation in multiple sclerosis and their mediating role for cognition: a randomized controlled trial.
     J Neurol. 2024 Apr 23. doi: 10.1007/s00415-024-12327.
     PubMed     Abstract available
     
     
     
142. SPIEZIA AL, Scalia G, Petracca M, Caliendo D, et al
     Effect of siponimod on lymphocyte subsets in active secondary progressive multiple sclerosis and clinical implications.
     J Neurol. 2024 Apr 17. doi: 10.1007/s00415-024-12362.
     PubMed     Abstract available
     
     
     
143. HIRT J, Dembowska K, Woelfle T, Axfors C, et al
     Clinical trial evidence of quality-of-life effects of disease-modifying therapies for multiple sclerosis: a systematic analysis.
     J Neurol. 2024 Apr 16. doi: 10.1007/s00415-024-12366.
     PubMed     Abstract available
     
     
     
144. SINGER BA, Feng J, Chiong-Rivero H
     Early use of high-efficacy therapies in multiple sclerosis in the United States: benefits, barriers, and strategies for encouraging adoption.
     J Neurol. 2024 Apr 14. doi: 10.1007/s00415-024-12305.
     PubMed     Abstract available
     
     
     
145. STALTER J, Pars K, Witt K
     Accelerated long-term forgetting reveals everyday memory deficits in early-stage multiple sclerosis.
     J Neurol. 2024 Apr 8. doi: 10.1007/s00415-024-12359.
     PubMed     Abstract available
     
     
     
146. CELIK M, Baba C, Irmak C, Ozakbas S, et al
     Risk of hepatitis B virus reactivation in people with multiple sclerosis treated with ocrelizumab: an observational study from Turkey.
     J Neurol. 2024 Apr 5. doi: 10.1007/s00415-024-12333.
     PubMed     Abstract available
     
     
     
147. STEFANOU MI, Giannopapas V, Kitsos DK, Chondrogianni M, et al
     Prevalence and epidemiology of stroke in patients with multiple sclerosis: a systematic review and meta-analysis.
     J Neurol. 2024 Apr 4. doi: 10.1007/s00415-024-12331.
     PubMed     Abstract available
     
     
     
148. MAIDA E, Moccia M, Palladino R, Borriello G, et al
     ChatGPT vs. neurologists: a cross-sectional study investigating preference, satisfaction ratings and perceived empathy in responses among people living with multiple sclerosis.
     J Neurol. 2024 Apr 3. doi: 10.1007/s00415-024-12328.
     PubMed     Abstract available
     
     
     
149. SIGNORIELLO E, Foschi M, Lanzillo R, Frau J, et al
     Pregnancy effect on disease activity in women with multiple sclerosis treated with cladribine.
     J Neurol. 2024 Apr 3. doi: 10.1007/s00415-024-12291.
     PubMed     Abstract available
     
     
     
150. GUERRIERI S, Rubin M, Gattuso I, Zanetta C, et al
     Can treatment adverse events be optimized by switching between different sphingosine 1-phosphate receptor modulators in multiple sclerosis? A case series.
     J Neurol. 2024 Apr 2. doi: 10.1007/s00415-024-12342.
     PubMed    
     
     
     
151. TEDONE N, Vizzino C, Meani A, Gallo A, et al
     The brief repeatable battery of neuropsychological tests (BRB-N) version a: update of Italian normative data from the Italian Neuroimaging Network Initiative (INNI).
     J Neurol. 2024;271:1813-1823.
     PubMed     Abstract available
     
     
     
152. GLASER A, Butzkueven H, van der Walt A, Gray O, et al
     Big Multiple Sclerosis Data network: an international registry research network.
     J Neurol. 2024 Apr 1. doi: 10.1007/s00415-024-12303.
     PubMed     Abstract available
     
     
     
153. HUA T, Fan H, Duan Y, Tian D, et al
     Spinal cord and brain atrophy patterns in neuromyelitis optica spectrum disorder and multiple sclerosis.
     J Neurol. 2024 Apr 1. doi: 10.1007/s00415-024-12281.
     PubMed     Abstract available
     
     
     March 2024
154. GUILLEMIN C, Vandeleene N, Charonitis M, Requier F, et al
     Brain microstructure is linked to cognitive fatigue in early multiple sclerosis.
     J Neurol. 2024 Mar 28. doi: 10.1007/s00415-024-12316.
     PubMed     Abstract available
     
     
     
155. SCHALLER-PAULE MA, Maiworm M, Schafer JH, Friedauer L, et al
     Matching proposed clinical and MRI criteria of aggressive multiple sclerosis to serum and cerebrospinal fluid markers of neuroaxonal and glial injury.
     J Neurol. 2024 Mar 27. doi: 10.1007/s00415-024-12299.
     PubMed     Abstract available
     
     
     
156. MALLUCCI G, Ferraro OE, Trojano M, Amato MP, et al
     Early prediction of unfavorable evolution after a first clinical episode suggestive of multiple sclerosis: the EUMUS score.
     J Neurol. 2024 Mar 26. doi: 10.1007/s00415-024-12304.
     PubMed     Abstract available
     
     
     
157. PILOTTO S, Floris M, Solla P, Pugliatti M, et al
     Determinants of self-perceived quality of life in mildly disabled multiple sclerosis patients: a cross-sectional study.
     J Neurol. 2024 Mar 25. doi: 10.1007/s00415-024-12244.
     PubMed     Abstract available
     
     
     
158. GOERECI Y, Ellenberger D, Rommer P, Dunkl V, et al
     Persons with multiple sclerosis older than 55 years: an analysis from the German MS registry.
     J Neurol. 2024 Mar 22. doi: 10.1007/s00415-024-12286.
     PubMed     Abstract available
     
     
     
159. ALBERGONI M, Pagani E, Preziosa P, Meani A, et al
     Thalamic nuclei volume partially mediates the effects of aerobic capacity on fatigue in people with multiple sclerosis.
     J Neurol. 2024 Mar 20. doi: 10.1007/s00415-024-12277.
     PubMed     Abstract available
     
     
     
160. ABDELGAIED MY, Rashad MH, El-Tayebi HM, Solayman MH, et al
     Correction to: The impact of metformin use on the outcomes of relapse?remitting multiple sclerosis patients receiving interferon beta 1a: an exploratory prospective phase II open?label randomized controlled trial.
     J Neurol. 2024 Mar 18. doi: 10.1007/s00415-024-12249.
     PubMed    
     
     
     
161. KRIJNEN EA, Broeders TAA, Noteboom S, van Dam M, et al
     The cognitive relevance of non-lesional damage to cortical networks in people with multiple sclerosis.
     J Neurol. 2024 Mar 5. doi: 10.1007/s00415-024-12240.
     PubMed     Abstract available
     
     
     
162. HEGEN H, Berek K, Deisenhammer F, Berger T, et al
     Sex impacts treatment decisions in multiple sclerosis.
     J Neurol. 2024 Mar 5. doi: 10.1007/s00415-024-12270.
     PubMed     Abstract available
     
     
     
163. HECHENBERGER S, Helmlinger B, Tinauer C, Jauk E, et al
     Evaluation of a self-administered iPad((R))-based processing speed assessment for people with multiple sclerosis in a clinical routine setting.
     J Neurol. 2024 Mar 5. doi: 10.1007/s00415-024-12274.
     PubMed     Abstract available
     
     
     
164. ZID Y, Robertson NP
     Extended interval dosing strategies in multiple sclerosis: insights from natalizumab and ocrelizumab trials.
     J Neurol. 2024 Mar 4. doi: 10.1007/s00415-024-12273.
     PubMed    
     
     
     
165. GUGER M, Enzinger C, Leutmezer F, Di Pauli F, et al
     Early intensive versus escalation treatment in patients with relapsing-remitting multiple sclerosis in Austria.
     J Neurol. 2024 Mar 2. doi: 10.1007/s00415-024-12256.
     PubMed     Abstract available
     
     
     February 2024
166. SCHERER L, Soudant M, Pittion-Vouyovitch S, Debouverie M, et al
     Risk of secondary progression in patients with highly active multiple sclerosis treated with natalizumab: a real-life study.
     J Neurol. 2024 Feb 29. doi: 10.1007/s00415-024-12266.
     PubMed     Abstract available
     
     
     
167. TOLJAN K, Briggs FBS
     Male sexual and reproductive health in multiple sclerosis: a scoping review.
     J Neurol. 2024 Feb 28. doi: 10.1007/s00415-024-12250.
     PubMed     Abstract available
     
     
     
168. LEAVITT VM, Tozlu C, Nelson KE, Boehme AK, et al
     A randomized controlled trial of oral antipyretic treatment to reduce overheating during exercise in adults with multiple sclerosis.
     J Neurol. 2024 Feb 28. doi: 10.1007/s00415-023-12147.
     PubMed     Abstract available
     
     
     
169. VAN DAM M, Krijnen EA, Nauta IM, Fuchs TA, et al
     Identifying and understanding cognitive profiles in multiple sclerosis: a role for visuospatial memory functioning.
     J Neurol. 2024 Feb 26. doi: 10.1007/s00415-024-12227.
     PubMed     Abstract available
     
     
     
170. CUTILLO G, Rubin M, d'Amore G, Malcangi M, et al
     Infratentorial posterior reversible encephalopathy syndrome in INFbeta1a-treated multiple sclerosis patient.
     J Neurol. 2024 Feb 22. doi: 10.1007/s00415-024-12226.
     PubMed    
     
     
     
171. BIANCHI A, Matranga D, Patti F, Maniscalco L, et al
     The role of ethnicity and native-country income in multiple sclerosis: the Italian multicentre study (MS-MigIT).
     J Neurol. 2024 Feb 16. doi: 10.1007/s00415-024-12214.
     PubMed     Abstract available
     
     
     
172. HARDING KE, Kreft KL, Ben-Shlomo Y, Robertson NP, et al
     Prodromal multiple sclerosis: considerations and future utility.
     J Neurol. 2024 Feb 11. doi: 10.1007/s00415-023-12173.
     PubMed     Abstract available
     
     
     January 2024
173. BAJRAMI A, Tamanti A, Peloso A, Ziccardi S, et al
     Ocrelizumab reduces cortical and deep grey matter loss compared to the S1P-receptor modulator in multiple sclerosis.
     J Neurol. 2024 Jan 30. doi: 10.1007/s00415-023-12179.
     PubMed     Abstract available
     
     
     
174. BOUMAN PM, van Dam MA, Jonkman LE, Steenwijk MD, et al
     Isolated cognitive impairment in people with multiple sclerosis: frequency, MRI patterns and its development over time.
     J Neurol. 2024 Jan 30. doi: 10.1007/s00415-024-12185.
     PubMed     Abstract available
     
     
     
175. NAUTA IM, Kessels RPC, Bertens D, Stam CJ, et al
     Neurophysiological brain function predicts response to cognitive rehabilitation and mindfulness in multiple sclerosis: a randomized trial.
     J Neurol. 2024 Jan 26. doi: 10.1007/s00415-024-12183.
     PubMed     Abstract available
     
     
     
176. FENG G, Posa S, Sureshkumar A, Simpson S, et al
     Experiences of people with multiple sclerosis and clinicians in using cognitive behavioural therapies for hidden symptoms: a systematic review and meta-aggregation.
     J Neurol. 2024 Jan 14. doi: 10.1007/s00415-023-12116.
     PubMed     Abstract available
     
     
     
177. ZHENG P, Sandroff BM, Motl RW
     Free-living ambulatory physical activity and cognitive function in multiple sclerosis: the significance of step rate vs. step volume.
     J Neurol. 2024 Jan 12. doi: 10.1007/s00415-023-12169.
     PubMed     Abstract available
     
     
     
178. MAILLART E, Todesco E, Assoumou L, Beigneux Y, et al
     Humoral response after accelerated schedule of HBV vaccination in MS patients before anti-CD20 therapy.
     J Neurol. 2024 Jan 11. doi: 10.1007/s00415-023-12175.
     PubMed    
     
     
     
179. TRYFONOS C, Chrysafi M, Vadikolias K, Berberoglou L, et al
     Nutritional interventional studies in patients with multiple sclerosis: a scoping review of the current clinical evidence.
     J Neurol. 2024 Jan 4. doi: 10.1007/s00415-023-12140.
     PubMed     Abstract available
     
     
     
180. LOREFICE L, Ferraro OE, Fenu G, Amato MP, et al
     Late-onset multiple sclerosis: disability trajectories in relapsing-remitting patients of the Italian MS Registry.
     J Neurol. 2024 Jan 3. doi: 10.1007/s00415-023-12152.
     PubMed     Abstract available
     
     
     
181. MOSER T, Zimmermann G, Baumgartner A, Berger T, et al
     Long-term outcome of natalizumab-associated progressive multifocal leukoencephalopathy in Austria: a nationwide retrospective study.
     J Neurol. 2024;271:374-385.
     PubMed     Abstract available
     
     
     December 2023
182. AZZIMONTI M, Margoni M, Zanetta C, Genovese F, et al
     Tumefactive demyelinating lesions: a challenging first manifestation of multiple sclerosis.
     J Neurol. 2023 Dec 28. doi: 10.1007/s00415-023-12164.
     PubMed    
     
     
     
183. IAFFALDANO P, Lucisano G, Guerra T, Patti F, et al
     Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry.
     J Neurol. 2023 Dec 22. doi: 10.1007/s00415-023-12137.
     PubMed     Abstract available
     
     
     
184. ANDORRA M, Freire A, Zubizarreta I, de Rosbo NK, et al
     Predicting disease severity in multiple sclerosis using multimodal data and machine learning.
     J Neurol. 2023 Dec 22. doi: 10.1007/s00415-023-12132.
     PubMed     Abstract available
     
     
     
185. MISTRI D, Valsasina P, Storelli L, Filippi M, et al
     Monoaminergic network dysfunction and development of depression in multiple sclerosis: a longitudinal investigation.
     J Neurol. 2023 Dec 19. doi: 10.1007/s00415-023-12138.
     PubMed     Abstract available
     
     
     
186. HABBESTAD A, Willumsen JS, Aarseth JH, Grytten N, et al
     Increasing age of multiple sclerosis onset from 1920 to 2022: a population-based study.
     J Neurol. 2023 Dec 14. doi: 10.1007/s00415-023-12047.
     PubMed     Abstract available
     
     
     
187. COVEY TJ, Golan D, Sergott R, Wilken J, et al
     Peering further into the mind's eye: combining visual evoked potential and optical coherence tomography measures enhances insight into the variance in cognitive functioning in multiple sclerosis.
     J Neurol. 2023 Dec 13. doi: 10.1007/s00415-023-12075.
     PubMed     Abstract available
     
     
     
188. ARROYO PEREIRO P, Munoz-Vendrell A, Leon Moreno I, Bau L, et al
     Baseline serum neurofilament light chain levels differentiate aggressive from benign forms of relapsing-remitting multiple sclerosis: a 20-year follow-up cohort.
     J Neurol. 2023 Dec 12. doi: 10.1007/s00415-023-12135.
     PubMed     Abstract available
     
     
     
189. TSAI CC, Jette S, Tremlett H
     Disease-modifying therapies used to treat multiple sclerosis and the gut microbiome: a systematic review.
     J Neurol. 2023 Dec 11. doi: 10.1007/s00415-023-12107.
     PubMed     Abstract available
     
     
     
190. ABDELGAIED MY, Rashad MH, El-Tayebi HM, Solayman MH, et al
     The impact of metformin use on the outcomes of relapse-remitting multiple sclerosis patients receiving interferon beta 1a: an exploratory prospective phase II open-label randomized controlled trial.
     J Neurol. 2023 Dec 9. doi: 10.1007/s00415-023-12113.
     PubMed     Abstract available
     
     
     November 2023
191. MEYER-ARNDT L, Brasanac J, Gamradt S, Bellmann-Strobl J, et al
     Body mass, neuro-hormonal stress processing, and disease activity in lean to obese people with multiple sclerosis.
     J Neurol. 2023 Nov 27. doi: 10.1007/s00415-023-12100.
     PubMed     Abstract available
     
     
     
192. MISTRI D, Tedone N, Biondi D, Vizzino C, et al
     Cognitive phenotypes in multiple sclerosis: mapping the spectrum of impairment.
     J Neurol. 2023 Nov 26. doi: 10.1007/s00415-023-12102.
     PubMed     Abstract available
     
     
     
193. JAKIMOVSKI D, Kavak KS, Coyle PK, Goodman AD, et al
     Disease-modifying treatment, long-term outcomes and transition to progressive multiple sclerosis: data based on the New York State MS Consortium.
     J Neurol. 2023 Nov 23. doi: 10.1007/s00415-023-12099.
     PubMed     Abstract available
     
     
     
194. BISECCO A, Matrone F, Capobianco M, De Luca G, et al
     COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients.
     J Neurol. 2023 Nov 20. doi: 10.1007/s00415-023-12084.
     PubMed     Abstract available
     
     
     
195. KENNEDY PGE, George W, Yu X
     The elusive nature of the oligoclonal bands in multiple sclerosis.
     J Neurol. 2023 Nov 9. doi: 10.1007/s00415-023-12081.
     PubMed     Abstract available
     
     
     
196. DI FILIPPO M, Ferraro D, Ragonese P, Prosperini L, et al
     SARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on relapse risk after the third booster dose.
     J Neurol. 2023 Nov 3. doi: 10.1007/s00415-023-12034.
     PubMed     Abstract available
     
     
     
197. FROHLICH K, Mrochen A, Wang R, Haupenthal D, et al
     Cerebral lesions sites in neurosarcoidosis: a lesion mapping study.
     J Neurol. 2023;270:5392-5397.
     PubMed     Abstract available
     
     
     
198. JEANTIN L, Shor N, Pallix-Guyot M, Roos-Weil D, et al
     Halting progressive multifocal leukoencephalopathy with pembrolizumab: the case of a patient with multiple sclerosis under fingolimod.
     J Neurol. 2023 Nov 1. doi: 10.1007/s00415-023-12055.
     PubMed    
     
     
     October 2023
199. MANTERO V, Cordano C, Balgera R, Basilico P, et al
     Serum sickness in a multiple sclerosis patient treated with ocrelizumab.
     J Neurol. 2023 Oct 31. doi: 10.1007/s00415-023-12082.
     PubMed    
     
     
     
200. KAPPOS L, Traboulsee A, Li DKB, Bar-Or A, et al
     Ocrelizumab exposure in relapsing-remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension.
     J Neurol. 2023 Oct 31. doi: 10.1007/s00415-023-11943.
     PubMed     Abstract available
     
     
     
201. DELGADO SR, Faissner S, Linker RA, Rammohan K, et al
     Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment.
     J Neurol. 2023 Oct 31. doi: 10.1007/s00415-023-12007.
     PubMed     Abstract available
     
     
     
202. RIVEL M, Achiron A, Stern Y, Zeilig G, et al
     Emotional burden among MS patients: associations between specific chronic pain diagnoses and psychological features.
     J Neurol. 2023 Oct 24. doi: 10.1007/s00415-023-12048.
     PubMed     Abstract available
     
     
     
203. ONTANEDA D, Chitnis T, Rammohan K, Obeidat AZ, et al
     Identification and management of subclinical disease activity in early multiple sclerosis: a review.
     J Neurol. 2023 Oct 21. doi: 10.1007/s00415-023-12021.
     PubMed     Abstract available
     
     
     
204. ZINGANELL A, Gobel G, Berek K, Hofer B, et al
     Multiple sclerosis in the elderly: a retrospective cohort study.
     J Neurol. 2023 Oct 19. doi: 10.1007/s00415-023-12041.
     PubMed     Abstract available
     
     
     
205. SELMAJ K, Cree BAC, Barnett M, Thompson A, et al
     Multiple sclerosis: time for early treatment with high-efficacy drugs.
     J Neurol. 2023 Oct 18. doi: 10.1007/s00415-023-11969.
     PubMed     Abstract available
     
     
     
206. RAVANO V, Piredda GF, Krasensky J, Andelova M, et al
     Tract-wise microstructural analysis informs on current and future disability in early multiple sclerosis.
     J Neurol. 2023 Oct 11. doi: 10.1007/s00415-023-12023.
     PubMed     Abstract available
     
     
     September 2023
207. RODRIGUEZ DE VERA GOMEZ P, Mendez Muros M, Torres Cuadro A, Toyos Saenz de Miera FJ, et al
     Alemtuzumab induces severe orbitopathy in relapsing-remitting multiple sclerosis.
     J Neurol. 2023 Sep 29. doi: 10.1007/s00415-023-11995.
     PubMed     Abstract available
     
     
     
208. LI Y, Saul A, Taylor B, Ponsonby AL, et al
     Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies.
     J Neurol. 2023 Sep 28. doi: 10.1007/s00415-023-11980.
     PubMed     Abstract available
     
     
     
209. WEEDA MM, van Nederpelt DR, Twisk JWR, Brouwer I, et al
     Multimodal MRI study on the relation between WM integrity and connected GM atrophy and its effect on disability in early multiple sclerosis.
     J Neurol. 2023 Sep 17. doi: 10.1007/s00415-023-11937.
     PubMed     Abstract available
     
     
     
210. FILIPPI M, Grimaldi L, Conte A, Totaro R, et al
     Intravenous or subcutaneous natalizumab in patients with relapsing-remitting multiple sclerosis: investigation on efficiency and savings-the EASIER study.
     J Neurol. 2023 Sep 16. doi: 10.1007/s00415-023-11955.
     PubMed     Abstract available
     
     
     
211. MCARTHUR C, Daruwalla C, Jayeskara M, Brown JWL, et al
     Robust real-world evidence: optimising disease-modifying treatments for multiple sclerosis.
     J Neurol. 2023 Sep 12. doi: 10.1007/s00415-023-11984.
     PubMed    
     
     
     
212. JACOBS BM, Tank P, Bestwick JP, Noyce AJ, et al
     Modifiable risk factors for multiple sclerosis have consistent directions of effect across diverse ethnic backgrounds: a nested case-control study in an English population-based cohort.
     J Neurol. 2023 Sep 7. doi: 10.1007/s00415-023-11971.
     PubMed     Abstract available
     
     
     August 2023
213. FERRAND M, Epstein J, Soudant M, Guillemin F, et al
     Real-life evaluation of the 2017 McDonald criteria for relapsing-remitting multiple sclerosis after a clinically isolated syndrome confirms a gain in time-to-diagnosis.
     J Neurol. 2023 Aug 31. doi: 10.1007/s00415-023-11905.
     PubMed     Abstract available
     
     
     
214. BONACCHI R, Valsasina P, Pagani E, Meani A, et al
     Sex-related differences in upper limb motor function in healthy subjects and multiple sclerosis patients: a multiparametric MRI study.
     J Neurol. 2023 Aug 28. doi: 10.1007/s00415-023-11948.
     PubMed     Abstract available
     
     
     
215. TOSCANO S, Chisari CG, Lo Fermo S, Gulino G, et al
     A dynamic interpretation of kappaFLC index for the diagnosis of multiple sclerosis: a change of perspective.
     J Neurol. 2023 Aug 28. doi: 10.1007/s00415-023-11952.
     PubMed     Abstract available
     
     
     
216. JAKIMOVSKI D, Zivadinov R, Weinstock Z, Fuchs TA, et al
     Cortical thickness and cognition in older people with multiple sclerosis.
     J Neurol. 2023 Aug 27. doi: 10.1007/s00415-023-11945.
     PubMed     Abstract available
     
     
     
217. SPIERER R, Lavi I, Bloch S, Mazar M, et al
     Risk of breakthrough COVID-19 after vaccination among people with multiple sclerosis on disease-modifying therapies.
     J Neurol. 2023 Aug 17. doi: 10.1007/s00415-023-11935.
     PubMed     Abstract available
     
     
     
218. KLETENIK I, Cohen AL, Glanz BI, Ferguson MA, et al
     Multiple sclerosis lesions that impair memory map to a connected memory circuit.
     J Neurol. 2023 Aug 2. doi: 10.1007/s00415-023-11907.
     PubMed     Abstract available
     
     
     July 2023
219. TILSLEY P, Strohmeyer IA, Heinrich I, Rosenthal F, et al
     Correction to: Physical fitness moderates the association between brain network impairment and both motor function and cognition in progressive multiple sclerosis.
     J Neurol. 2023 Jul 26. doi: 10.1007/s00415-023-11874.
     PubMed    
     
     
     
220. NOTEBOOM S, van Nederpelt DR, Bajrami A, Moraal B, et al
     Feasibility of detecting atrophy relevant for disability and cognition in multiple sclerosis using 3D-FLAIR.
     J Neurol. 2023 Jul 19. doi: 10.1007/s00415-023-11870.
     PubMed     Abstract available
     
     
     
221. ROCCA MA, Valsasina P, Lamanna MT, Colombo B, et al
     Functional connectivity modifications in monoaminergic circuits occur in fatigued MS patients treated with fampridine and amantadine.
     J Neurol. 2023 Jul 18. doi: 10.1007/s00415-023-11858.
     PubMed     Abstract available
     
     
     
222. LOMBARDO-DEL TORO P, Bragado-Trigo I, Arroyo P, Tena-Cucala R, et al
     Fingolimod-associated progressive multifocal leukoencephalopathy in a multiple sclerosis patient with a good response to filgrastim.
     J Neurol. 2023 Jul 17. doi: 10.1007/s00415-023-11865.
     PubMed    
     
     
     
223. PETROU P, Achiron A, Cohen EG, Garty M, et al
     Practical recommendations on treatment of multiple sclerosis with Cladribine: an Israeli Experts Group‏ Viewpoint.
     J Neurol. 2023 Jul 12. doi: 10.1007/s00415-023-11846.
     PubMed     Abstract available
     
     
     
224. AMATO MP, Bergamaschi R, Centonze D, Mirabella M, et al
     Effectiveness of teriflunomide on No Evidence of Disease Activity and cognition in relapsing remitting multiple sclerosis: results of the NEDA3PLUS study.
     J Neurol. 2023 Jul 5. doi: 10.1007/s00415-023-11820.
     PubMed     Abstract available
     
     
     
225. NICULAE AS, Niculae LE, Vacaras C, Vacaras V, et al
     Serum levels of neurofilament light chains in pediatric multiple sclerosis: a systematic review and meta-analysis.
     J Neurol. 2023 Jul 2. doi: 10.1007/s00415-023-11841.
     PubMed     Abstract available
     
     
     
226. JARIUS S, Aktas O, Ayzenberg I, Bellmann-Strobl J, et al
     Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis.
     J Neurol. 2023;270:3341-3368.
     PubMed     Abstract available
     
     
     June 2023
227. RUGGIERI S, Prosperini L, Petracca M, Logoteta A, et al
     The added value of spinal cord lesions to disability accrual in multiple sclerosis.
     J Neurol. 2023 Jun 29. doi: 10.1007/s00415-023-11829.
     PubMed     Abstract available
     
     
     
228. TILSLEY P, Strohmeyer IA, Heinrich I, Rosenthal F, et al
     Physical fitness moderates the association between brain network impairment and both motor function and cognition in progressive multiple sclerosis.
     J Neurol. 2023 Jun 21. doi: 10.1007/s00415-023-11806.
     PubMed     Abstract available
     
     
     
229. ROSENSTEIN I, Axelsson M, Novakova L, Malmestrom C, et al
     Intrathecal kappa free light chain synthesis is associated with worse prognosis in relapsing-remitting multiple sclerosis.
     J Neurol. 2023 Jun 14. doi: 10.1007/s00415-023-11817.
     PubMed     Abstract available
     
     
     
230. GRANGE E, Solaro C, Di Giovanni R, Marengo D, et al
     The correlation between 9-HPT and patient-reported measures of upper limb function in multiple sclerosis: a systematic review and meta-analysis.
     J Neurol. 2023 Jun 9. doi: 10.1007/s00415-023-11801.
     PubMed     Abstract available
     
     
     
231. MONSCHEIN T, Dekany S, Zrzavy T, Ponleitner M, et al
     Correction: Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR).
     J Neurol. 2023 Jun 5. doi: 10.1007/s00415-023-11784.
     PubMed    
     
     
     
232. HOLTZER R, Choi J, Motl RW, Foley FW, et al
     Individual reserve in aging and neurological disease.
     J Neurol. 2023;270:3179-3191.
     PubMed     Abstract available
     
     
     May 2023
233. LOUAPRE C, Rosenzwajg M, Golse M, Roux A, et al
     A randomized double-blind placebo-controlled trial of low-dose interleukin-2 in relapsing-remitting multiple sclerosis.
     J Neurol. 2023 May 28. doi: 10.1007/s00415-023-11690.
     PubMed     Abstract available
     
     
     
234. AZZIMONTI M, Preziosa P, Pagani E, Valsasina P, et al
     Functional and structural brain MRI changes associated with cognitive worsening in multiple sclerosis: a 3-year longitudinal study.
     J Neurol. 2023 May 18. doi: 10.1007/s00415-023-11778.
     PubMed     Abstract available
     
     
     
235. ZANETTA C, Rocca MA, Meani A, Martinelli V, et al
     Correction to: Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing-remitting multiple sclerosis patients: a monocentric longitudinal observational study.
     J Neurol. 2023 May 17. doi: 10.1007/s00415-023-11772.
     PubMed    
     
     
     
236. MUNOZ-VENDRELL A, Arroyo-Pereiro P, Leon I, Bau L, et al
     Natalizumab continuation versus switching to ocrelizumab after PML risk stratification in RRMS patients: a natural experiment.
     J Neurol. 2023;270:2559-2566.
     PubMed     Abstract available
     
     
     April 2023
237. KREMMYDA O, Feil K, Bardins S, Strupp M, et al
     Acetyl-DL-leucine in combination with memantine improves acquired pendular nystagmus caused by multiple sclerosis: a case report.
     J Neurol. 2023 Apr 27. doi: 10.1007/s00415-023-11730.
     PubMed    
     
     
     
238. VAN DAM M, de Jong BA, Willemse EAJ, Nauta IM, et al
     A multimodal marker for cognitive functioning in multiple sclerosis: the role of NfL, GFAP and conventional MRI in predicting cognitive functioning in a prospective clinical cohort.
     J Neurol. 2023 Apr 27. doi: 10.1007/s00415-023-11676.
     PubMed     Abstract available
     
     
     
239. MARGONI M, Pagani E, Preziosa P, Gueye M, et al
     Unraveling the heterogeneous pathological substrates of relapse-onset multiple sclerosis: a multiparametric voxel-wise 3 T MRI study.
     J Neurol. 2023 Apr 24. doi: 10.1007/s00415-023-11736.
     PubMed     Abstract available
     
     
     
240. KOUTSOURAKI E, Theodoros K, Eleni G, Marianna K, et al
     Autonomic nervous system disorders in multiple sclerosis.
     J Neurol. 2023 Apr 21. doi: 10.1007/s00415-023-11725.
     PubMed     Abstract available
     
     
     
241. MONSCHEIN T, Dekany S, Zrzavy T, Ponleitner M, et al
     Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR).
     J Neurol. 2023 Apr 19. doi: 10.1007/s00415-023-11686.
     PubMed     Abstract available
     
     
     
242. GANAPATHY SUBRAMANIAN R, Zivadinov R, Bergsland N, Dwyer MG, et al
     Multiple sclerosis optic neuritis and trans-synaptic pathology on cortical thinning in people with multiple sclerosis.
     J Neurol. 2023 Apr 17. doi: 10.1007/s00415-023-11709.
     PubMed     Abstract available
     
     
     
243. YEO T, Siew RWE, Gulam MY, Tye JSN, et al
     COVID-19 infection after SARS-CoV-2 mRNA vaccination in Multiple Sclerosis, AQP4-antibody NMOSD and MOGAD patients during the Omicron subvariant BA.1/2 wave in Singapore.
     J Neurol. 2023 Apr 7:1-9. doi: 10.1007/s00415-023-11692.
     PubMed     Abstract available
     
     
     
244. ZANETTA C, Rocca MA, Meani A, Martinelli V, et al
     Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing-remitting multiple sclerosis patients: a monocentric longitudinal observational study.
     J Neurol. 2023 Apr 7:1-12. doi: 10.1007/s00415-023-11700.
     PubMed     Abstract available
     
     
     
245. VRENKEN H, Battaglini M, de Vos ML, Nagtegaal GJ, et al
     Temporal evolution of new T1-weighted hypo-intense lesions and central brain atrophy in patients with a first clinical demyelinating event treated with subcutaneous interferon beta-1a.
     J Neurol. 2023;270:2271-2282.
     PubMed     Abstract available
     
     
     
246. LEHTO J, Sucksdorff M, Nylund M, Raitanen R, et al
     PET-measurable innate immune cell activation reduction in chronic active lesions in PPMS brain after rituximab treatment: a case report.
     J Neurol. 2023;270:2329-2332.
     PubMed     Abstract available
     
     
     
247. ASTBURY L, Kalra S, Tanasescu R, Constantinescu CS, et al
     CSF lymphocytic pleocytosis does not predict a less favourable long-term prognosis in MS.
     J Neurol. 2023;270:2042-2047.
     PubMed     Abstract available
     
     
     March 2023
248. PLESS S, Woelfle T, Naegelin Y, Lorscheider J, et al
     Assessment of cognitive performance in multiple sclerosis using smartphone-based training games: a feasibility study.
     J Neurol. 2023 Mar 23. doi: 10.1007/s00415-023-11671.
     PubMed     Abstract available
     
     
     
249. TORRES P, Sancho-Saldana A, Gil Sanchez A, Peralta S, et al
     A prospective study of cellular immune response to booster COVID-19 vaccination in multiple sclerosis patients treated with a broad spectrum of disease-modifying therapies.
     J Neurol. 2023 Mar 18:1-12. doi: 10.1007/s00415-023-11575.
     PubMed     Abstract available
     
     
     
250. ROMANO F, Motl RW, Valsasina P, Amato MP, et al
     Abnormal thalamic functional connectivity correlates with cardiorespiratory fitness and physical activity in progressive multiple sclerosis.
     J Neurol. 2023 Mar 18. doi: 10.1007/s00415-023-11664.
     PubMed     Abstract available
     
     
     
251. DE ROSA AP, Esposito F, Valsasina P, d'Ambrosio A, et al
     Correction to: Resting-state functional MRI in multicenter studies on multiple sclerosis: a report on raw data quality and functional connectivity features from the Italian Neuroimaging Network Initiative.
     J Neurol. 2023 Mar 13. doi: 10.1007/s00415-023-11646.
     PubMed    
     
     
     
252. MOGAVERO MP, Lanza G, Bruni O, DelRosso LM, et al
     Sleep counts! Role and impact of sleep in the multimodal management of multiple sclerosis.
     J Neurol. 2023 Mar 11. doi: 10.1007/s00415-023-11655.
     PubMed     Abstract available
     
     
     
253. VELDKAMP R, D'hooge M, Sandroff BM, DeLuca J, et al
     Profiling cognitive-motor interference in a large sample of persons with progressive multiple sclerosis and impaired processing speed: results from the CogEx study.
     J Neurol. 2023 Mar 7. doi: 10.1007/s00415-023-11636.
     PubMed     Abstract available
     
     
     
254. LI G, You Q, Hou X, Zhang S, et al
     The effect of exercise on cognitive function in people with multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials.
     J Neurol. 2023 Mar 2. doi: 10.1007/s00415-023-11649.
     PubMed     Abstract available
     
     
     
255. GUGER M, Enzinger C, Leutmezer F, Di Pauli F, et al
     Effects of horizontal versus vertical switching of disease-modifying treatment after platform drugs on disease activity in patients with relapsing-remitting multiple sclerosis in Austria.
     J Neurol. 2023 Mar 2. doi: 10.1007/s00415-023-11644.
     PubMed     Abstract available
     
     
     
256. BARLETTA VT, Herranz E, Treaba CA, Mehndiratta A, et al
     In vivo characterization of microglia and myelin relation in multiple sclerosis by combined (11)C-PBR28 PET and synthetic MRI.
     J Neurol. 2023 Mar 2. doi: 10.1007/s00415-023-11621.
     PubMed     Abstract available
     
     
     
257. DIETMANN AS, Kruse N, Stork L, Gloth M, et al
     Neurofilament light chains in serum as biomarkers of axonal damage in early MS lesions: a histological-serological correlative study.
     J Neurol. 2023;270:1416-1429.
     PubMed     Abstract available
     
     
     February 2023
258. BAETGE SJ, Filser M, Renner A, Raithel LM, et al
     Supporting brain health in multiple sclerosis: exploring the potential of neuroeducation combined with practical mindfulness exercises in the management of neuropsychological symptoms.
     J Neurol. 2023 Feb 25:1-14. doi: 10.1007/s00415-023-11616.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Multiple Sclerosis is free of charge.